References
1. Hartholt KA, van Beeck EF, Polinder S, et al. Societal consequences
of falls in the older population: injuries, healthcare costs, and
long-term reduced quality of life. The Journal of trauma . Sep
2011;71(3):748-53. doi:10.1097/TA.0b013e3181f6f5e5
2. falls CfDCaPHaRSIfa.http://www.cdc.gov/homeandrecreationalsafety/falls/adultfalls.html .
Accessed October 16, 2020.
3. Seppala LJ, van der Velde N, Masud T, et al. EuGMS Task and Finish
group on Fall-Risk-Increasing Drugs (FRIDs): Position on Knowledge
Dissemination, Management, and Future Research. Drugs Aging . Apr
2019;36(4):299-307. doi:10.1007/s40266-018-0622-7
4. Seppala LJ, Wermelink A, de Vries M, et al. Fall-Risk-Increasing
Drugs: A Systematic Review and Meta-Analysis: II. Psychotropics.Journal of the American Medical Directors Association . Apr
2018;19(4):371.e11-371.e17. doi:10.1016/j.jamda.2017.12.098
5. Seppala LJ, Petrovic M, Ryg J, et al. STOPPFall (Screening Tool of
Older Persons Prescriptions in older adults with high fall risk): a
Delphi study by the EuGMS Task and Finish Group on Fall-Risk-Increasing
Drugs. Age and ageing . Dec 22 2020;doi:10.1093/ageing/afaa249
6. Iaboni A, Flint AJ. The complex interplay of depression and falls in
older adults: a clinical review. The American journal of geriatric
psychiatry : official journal of the American Association for Geriatric
Psychiatry . May 2013;21(5):484-92. doi:10.1016/j.jagp.2013.01.008
7. van Poelgeest EP, Pronk AC, Rhebergen D, van der Velde N. Depression,
antidepressants and fall risk: therapeutic dilemmas-a clinical review.Eur Geriatr Med . Jun 2021;12(3):585-596.
doi:10.1007/s41999-021-00475-7
8. Chen Y, Zhu LL, Zhou Q. Effects of drug
pharmacokinetic/pharmacodynamic properties, characteristics of
medication use, and relevant pharmacological interventions on fall risk
in elderly patients. Ther Clin Risk Manag . 2014;10:437-48.
doi:10.2147/tcrm.S63756
9. Coupland CA, Dhiman P, Barton G, et al. A study of the safety and
harms of antidepressant drugs for older people: a cohort study using a
large primary care database. Health Technol Assess . Aug
2011;15(28):1-202, iii-iv. doi:10.3310/hta15280
10. Lotrich FE, Pollock BG. Aging and clinical pharmacology:
implications for antidepressants. J Clin Pharmacol . Oct
2005;45(10):1106-22. doi:10.1177/0091270005280297
11. Sultana J, Spina E, Trifirò G. Antidepressant use in the elderly:
the role of pharmacodynamics and pharmacokinetics in drug safety.Expert opinion on drug metabolism & toxicology . Jun
2015;11(6):883-92. doi:10.1517/17425255.2015.1021684
12. Spina E, Scordo MG. Clinically significant drug interactions with
antidepressants in the elderly. Drugs & aging .
2002;19(4):299-320. doi:10.2165/00002512-200219040-00004
13. Hiemke C, Bergemann N, Clement HW, et al. Consensus Guidelines for
Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017.Pharmacopsychiatry . Jan 2018;51(1-02):9-62.
doi:10.1055/s-0043-116492
14. van Wijngaarden JP, Dhonukshe-Rutten RA, van Schoor NM, et al.
Rationale and design of the B-PROOF study, a randomized controlled trial
on the effect of supplemental intake of vitamin B12 and folic acid on
fracture incidence. BMC geriatrics . Dec 2 2011;11:80.
doi:10.1186/1471-2318-11-80
15. Swart KM, Ham AC, van Wijngaarden JP, et al. A Randomized Controlled
Trial to Examine the Effect of 2-Year Vitamin B12 and Folic Acid
Supplementation on Physical Performance, Strength, and Falling:
Additional Findings from the B-PROOF Study. Calcified tissue
international . Jan 2016;98(1):18-27. doi:10.1007/s00223-015-0059-5
16. ATC and DDD index. WHO Collaborating Centre for Drug Statistics
Methodology, Oslo . https://www.whocc.no/atc_ddd_index/ .
17. The prevention of falls in later life. A report of the Kellogg
International Work Group on the Prevention of Falls by the Elderly.Danish medical bulletin . Apr 1987;34 Suppl 4:1-24.
18. Gnjidic D, Hilmer SN, Blyth FM, et al. Polypharmacy cutoff and
outcomes: five or more medicines were used to identify
community-dwelling older men at risk of different adverse outcomes.J Clin Epidemiol . Sep 2012;65(9):989-95.
doi:10.1016/j.jclinepi.2012.02.018
19. Debonnel G, Saint-Andre E, Hebert C, de Montigny C, Lavoie N, Blier
P. Differential physiological effects of a low dose and high doses of
venlafaxine in major depression. Int J Neuropsychopharmacol . Feb
2007;10(1):51-61. doi:10.1017/S1461145705006413
20. Bujang MA, Sa’at N, Sidik T, Joo LC. Sample Size Guidelines for
Logistic Regression from Observational Studies with Large Population:
Emphasis on the Accuracy Between Statistics and Parameters Based on Real
Life Clinical Data. Malays J Med Sci . Jul 2018;25(4):122-130.
doi:10.21315/mjms2018.25.4.12
21. Hartholt KA, Becker ML, van der Cammen TJ. Drug-induced falls in
older persons: is there a role for therapeutic drug monitoring?Ther Adv Drug Saf . Apr 2016;7(2):39-42.
doi:10.1177/2042098615627806
22. Rodriguez de la Torre B, Dreher J, Malevany I, et al. Serum levels
and cardiovascular effects of tricyclic antidepressants and selective
serotonin reuptake inhibitors in depressed patients. Ther Drug
Monit . Aug 2001;23(4):435-40. doi:10.1097/00007691-200108000-00019
23. Mol A, Bui Hoang PTS, Sharmin S, et al. Orthostatic Hypotension and
Falls in Older Adults: A Systematic Review and Meta-analysis.Journal of the American Medical Directors Association . May
2019;20(5):589-597.e5. doi:10.1016/j.jamda.2018.11.003
24. Chew ML, Mulsant BH, Pollock BG, et al. Anticholinergic activity of
107 medications commonly used by older adults. Journal of the
American Geriatrics Society . Jul 2008;56(7):1333-41.
doi:10.1111/j.1532-5415.2008.01737.x
25. Drenth-van Maanen AC, Wilting I, Jansen PAF. Prescribing medicines
to older people-How to consider the impact of ageing on human organ and
body functions. Br J Clin Pharmacol . Oct 2020;86(10):1921-1930.
doi:10.1111/bcp.14094
26. Eap CB, Gründer G, Baumann P, et al. Tools for optimising
pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular
brain imaging and pharmacogenetic tests): focus on antidepressants.World J Biol Psychiatry . May 12 2021:1-68.
doi:10.1080/15622975.2021.1878427
27. Asberg M, Cronholm B, Sjöqvist F, Tuck D. Correlation of subjective
side effects with plasma concentrations of nortriptyline. Br Med
J . Oct 3 1970;4(5726):18-21. doi:10.1136/bmj.4.5726.18
28. Asberg M, Crönholm B, Sjöqvist F, Tuck D. Relationship between
plasma level and therapeutic effect of nortriptyline. Br Med J .
Aug 7 1971;3(5770):331-4. doi:10.1136/bmj.3.5770.331
29. Ostad Haji E, Hiemke C, Pfuhlmann B. Therapeutic drug monitoring for
antidepressant drug treatment. Curr Pharm Des .
2012;18(36):5818-27. doi:10.2174/138161212803523699
30. Hermann M, Waade RB, Molden E. Therapeutic Drug Monitoring of
Selective Serotonin Reuptake Inhibitors in Elderly Patients. Ther
Drug Monit . Aug 2015;37(4):546-9. doi:10.1097/ftd.0000000000000169
31. Wyska E. Pharmacokinetic considerations for current state-of-the-art
antidepressants. Expert opinion on drug metabolism & toxicology .
Oct 2019;15(10):831-847. doi:10.1080/17425255.2019.1669560
32. Baumann P, Hiemke C, Ulrich S, et al. The AGNP-TDM expert group
consensus guidelines: therapeutic drug monitoring in psychiatry.Pharmacopsychiatry . Nov 2004;37(6):243-65.
doi:10.1055/s-2004-832687
33. Waade RB, Molden E, Refsum H, Hermann M. Serum concentrations of
antidepressants in the elderly. Ther Drug Monit . Feb
2012;34(1):25-30. doi:10.1097/FTD.0b013e318241dce0
34. Tveit K, Hermann M, Waade RB, Nilsen RM, Wallerstedt SM, Molden E.
Use of Antidepressants in Older People during a 10-Year Period: An
Observational Study on Prescribed Doses and Serum Levels. Drugs &
aging . Sep 2020;37(9):691-701. doi:10.1007/s40266-020-00784-9
35. Lundmark J, Bengtsson F, Nordin C, Reis M, Wålinder J. Therapeutic
drug monitoring of selective serotonin reuptake inhibitors influences
clinical dosing strategies and reduces drug costs in depressed elderly
patients. Acta psychiatrica Scandinavica . May 2000;101(5):354-9.
doi:10.1034/j.1600-0447.2000.101005354.x
36. Ostad Haji E, Tadić A, Wagner S, et al. Association between
citalopram serum levels and clinical improvement of patients with major
depression. Journal of clinical psychopharmacology . Jun
2011;31(3):281-6. doi:10.1097/JCP.0b013e318218f503
37. Lamb SE, Jørstad-Stein EC, Hauer K, Becker C. Development of a
common outcome data set for fall injury prevention trials: the
Prevention of Falls Network Europe consensus. Journal of the
American Geriatrics Society . Sep 2005;53(9):1618-22.
doi:10.1111/j.1532-5415.2005.53455.x